Several known variants of the reference sequence (NM_00053.1) were also found. These are c.1216T>G in exon 2 (Ser406Ala), ATP7B_E3_c.1366G>C in exon 3 (Val456Leu), ATP7B_E10_c.2495A>G in exon 10 (Lys832Arg), c.2855G>A in exon 12 (Arg952Lys), and c.3419C>T variant in exon 16 (Ala1140Val) (8). Two patients (siblings WDH_21.003 and 21.004) did not present with any known mutations, whereas another patient (WDH_23.003) only presented with a single mutant ATP7B allele.
Liver biopsies were obtained from all of the patients, and hepatic lesions were graded by using a semiquantitative evaluation protocol, based on a methodology previously developed for chronic hepatitis (32,33). This classification is widely accepted to evaluate hepatic damage and describes, on one hand, the damage to hepatocytes and inflammation (necroinflammatory process) and, on the other hand, the structural damage (fibrosis), shown to be more reproducible.
All of the patients presented with some degree of alterations in the hepatic biopsies. These ranged from mild alterations with micro- and macrovesicular steatosis to cirrhosis. Histological lesions were well developed before the disease was clinically evident. The results of these analyses are summarized in Table 3.
In initial stages of the disease, fatty liver degeneration (steatosis), evidenced by the presence of small and large lipid droplets (micro- and macrosteatosis, respectively), was present in all of the patients and was progressively associated with lobular activity. In elderly patients, portal/periportal activity becomes more severe, evolving to perinodular fibrosis.
Treatment and Follow-up
All of the patients were initially treated with D-penicillamine and vitamin B6 and were advised to follow a low-copper diet. Once urinary copper levels fell below 500 μg/day, D-penicillamine treatment was discontinued and zinc acetate was then administered as maintenance treatment. Treatment was well tolerated and the clinical progress had been satisfactory in all of the cases. The levels of transaminases were normalized after 15 to 16 months in all of the patients except WDH_21003, who recovered normal transaminemia levels after a 20-month treatment period. The heterozygote group includes patient WDH_25003, which showed intense hepatic alterations. Even though all of the patients showed no sign of disease after treatment, 2 L708P homozygotes (WDH_26003, WDH_24003) and 2 heterozygotes (WDH_23003, WDH_19006) still presented with a mild sustained hypertransaminemia that persisted even after treatment. Adverse drug reactions (ADRs) were not detected in any of the patients treated.
Only 2 patients from the heterozygote group showed some nondisabling symptoms such as anorexia and ponderal retardation (WDH_18003), or sustained pain on the right hypochondrium (WDH_19006). All of the patients, with the exception of WDH_18003, grew normally within the 10th to 90th weight and height percentile values for their age.
During diagnosis and follow-up, 3 heterozygotes (WDH_23003, WDH_18003, WDH_19006), 1 homozygote (WDH_26003), and 1 patient with no known mutation (WDH_21003) showed elevated cholesterol levels ≥200 mg/dL. None of these were obese, had family history of hypercholesterolemia, or were apparently subjected to other causes that could explain these elevated cholesterol levels.
During follow-up, anti-nuclear (undetectable titer 1/80) and anti-cytoplasmic antibodies with a cytoskeletal pattern (undetectable titer = 1/320) were detected in 1 patient (WDH_23003). Patient WDH_28004 had been recently diagnosed and, therefore, the response to treatment has not been fully evaluated for this patient.
In the present study, we analyzed the early clinical manifestations of WD and the response to treatment of 11 pediatric patients ages 3 to 13 years with an elevated presence of the L708P mutation. Biochemical and pathological features, together with their response to treatment and clinical evolution, have been defined for this group of patients. Additionally, these patients, in conjunction with a previously described cohort (13), constitute one of the largest groups of patients with WD with high incidence of a single mutation, allowing us to define the clinical evolution of the disease in patients carrying the ATP7B L708P mutation.
The L708P mutation affects the second transmembrane domain of the ATP7B polypeptide, involved in copper transport. This mutation is greatly represented in the island of Gran Canaria (13), and it has been also found in other populations (23,34) but not in continental Spain (35,36). Also, in agreement with our previous study (13), the second most prevalent mutation found in our patients was the M645R, the most common in continental Spain (35).
The present study had also uncovered a novel variant on exon 18, at c.3796G>T, leading to a glycine-to-tryptophan amino acid change at position 1266 in the ATP hinge region of the ATP7B protein. This particular codon is subject to mutations at all 3 positions (22,23,30) and is greatly conserved within a motif likely involved in ATP binding and catalysis (31). Consistent with its presumed important role and its degree of conservation among similar ATPase domains from all phyla (Fig. 1), this mutation appears to be severe as evidenced by liver histological analysis of the affected heterozygote (WDH_25003), which showed severe cirrhosis at a relatively early age compared with other L708P compound heterozygotes. Based on these observations, we conclude that the c.3796G>T is indeed a mutant variant of the ATP7B gene.
We failed to detect mutations in 3 ATP7B alleles. In these cases, diagnosis was clear. Patient WDH_23003, with a single L708P mutant allele, presented with typical biochemical features: low ceruloplasmin and cupremia. Although cupruria was not significantly elevated, the patient showed a positive response to the PCT, and was appropriately managed with the standard treatment. As for the 2 siblings that did not bear any mutations in the ATP7B gene sequences analyzed (WDH_21003, WDH_21004), they also showed significant accumulation of hepatic copper, as well as decreased ceruloplasmin and cupremia. Although they were not subjected to a PCT, key clinical findings, together with a positive response to treatment, were considered sufficient to diagnose WD (14,37).
Previous studies on Spanish patients have failed to detect from 26% (35) up to 40% of the mutant alleles (36). Failure to detect mutations in the ATP7B gene in patients with a clear WD phenotype could be caused by, on one hand, technical reasons owing to a direct sequencing approach. On the other hand, it is plausible that other factors may influence the outcome of the disease, such as environmental and/or genetic conditions. Indeed, mice heterozygous for a null ATP7B allele have revealed genetic haploinsufficiency, because they develop WD symptoms when fed a high-copper diet (38). Similar pressure may be applied by specific variations in modifier genes, such as those coding for proteins that participate in the process of copper transport and detoxification (39). Whether human heterozygotes may show disease symptoms is an interesting issue that has been proposed previously (40) and should be explored further.
Hypertransaminemia is a typical feature of asymptomatic WD (41). In our series, detected by routine health checks, all of the patients were asymptomatic and only 1 case presented with manifestations of acute hepatitis (WDH_23003). In pediatric patients from a previous study in Gran Canaria, both hepatic and neurological symptoms are found in those that have been diagnosed at later stages (13). In the same study, which included only symptomatic patients, mostly adults, homozygosis for the L708P mutation correlates with a moderate-to-severe clinical presentation of WD, whereas compound heterozygotes appear to present with a milder disease manifestation. In the present study, both hypertransaminemia and decreased ceruloplasmin levels were unrelated to the presence of the L708P mutation in either homo- or heterozygosis: homozygotes and heterozygotes are phenotypically similar, and so are both when compared with other pediatric patients bearing different mutations. Spanish patients younger than 18 years reveal that the diagnosis of WD occurs during the presymptomatic stage in 75% to 80% of cases. Of these, 20% to 25% show hepatic (75%–92%) and/or neurological symptoms (8%–25%) (17). In patients younger than 10 years, 83% show some symptoms of hepatopathy, whereas in adolescence, up to half of the cases start to be affected by neurological manifestations (42).
Only 2 patients presented with basal cupruria levels above the diagnostic values expected for WD. This could be explained by inappropriate sample collection, or that the levels of urinary copper may change according to diet or other factors. Moreover, in patients with short-term asymptomatic hypertransaminemia, the accumulation and release of copper from hepatocytes may not be sufficient to reach the blood and be eliminated through the urine at significant levels. These findings are in agreement with similar studies in which the patients with lowest cupruria were those diagnosed based on family history (16,21). Therefore, we conclude that cupruria has a poor diagnostic value in young asymptomatic patients.
Hepatic copper content is, for many, unequivocal diagnostic proof of WD. Most of the patients (7/8) presented with copper hepatic levels >250 μg/g dry weight, regardless of age or whether the L708P mutation was present in homo- or heterozygosis, similar to what has been found in other groups (43).
One patient (WDH_23003) presented with autoantibodies. Similar autoimmune features have been also described in other studies (43,44). The value of this diagnostic test is unclear and only affects a small fraction of patients.
In our series, the discordance between the clinical symptoms and the hepatic alterations observed is remarkable. Histological lesions were well developed before the disease was clinically evident. In similar studies, chronic inflammatory portal inflammation and lobular cytolysis are often reported, and up to 75% of the cases present with steatosis and fibrosis, whereas advanced fibrosis is reported in up to 15% of cases (37). It must be noted that hepatitis and cirrhosis are sometimes difficult to distinguish from lesions of viral origin at the histological level and can therefore be confused with other hepatic pathologies. Neither acute hepatic failure nor encephalopathy was found in our patients at the time of diagnosis or follow-up, in contrast with other studies in which up to 57% of the patients presented with acute hepatic failure, with signs of encephalopathy in half of them (43).
The rate and time of normalization of aminotransferase levels in WD-affected children adherent to therapy are not well described. Aminotransferase levels seem to be a more reliable parameter of treatment efficacy in the early phase of WD than clinical signs such as fatigue, abdominal pain, or hepatomegaly. In agreement with similar studies (45), transaminase levels were normalized in 6 patients after an average period of 16 months of treatment with penicillamine. Three patients persisted with mild sustained hypertransaminemia after the initial decrease, whereas 1 had periodical peaks. The persistence of a mild sustained hypertransaminemia even after treatment is reported in other studies (46,47). Besides rare ADRs, nonadherence is the most common cause of increased liver enzyme levels in patients with WD receiving long-term therapy (47–49). This is probably the case in our patients, as concluded by interviewing children and their parents.
There is evidence showing that up to 70% of the patients treated with penicillamine may demonstrate ADRs, including hypersensitivity, bone marrow suppression, and development of autoimmune disease, and approximately 30% may experience severe adverse effects such as neurological deterioration, pancytopenia, nephrotoxicity, polyneuropathy, optic neuritis, and polymyositis (18). In pediatric patients, up to 13% of the patients were forced to discontinue treatment because of ADRs (45). We did not observe any ADRs in any of our patients, probably because the sample size is small compared with other studies.
During diagnosis and follow-up, up to 5 patients showed elevated cholesterol levels ≥200 mg/dL. To the best of our knowledge, none of these patients had a family history of hypercholesterolemia or were subjected to other causes that could explain these elevated cholesterol levels. Additionally, none of the patients was obese. Although we have not found evidence of this feature in other series of patients with WD, it is plausible that, as suggested by others (50), hypercholesterolemia is a consequence of the hepatic damage causing a decrease in the synthesis of the low-density lipoprotein receptor and apolipoproteins, or by an inhibitory effect exerted by copper on the latter. The patients who presented with hypercholesterolemia were not the most severely affected as determined by the examination of hepatic biopsies. In 3 of these patients, both hypertransaminemia and hypercholesterolemia were detected (WDH_23003, WDH_19006, WDH_26003), whereas in 2 (WDH_21003, WDH_18003), high cholesterol levels were not accompanied by elevated transaminemia.
The clinical evolution of patients bearing the L708P mutation, found in the present study and in a previous study (13), was summarized in Table 4. The data show that, although with a variable histological lesion, hepatocellular damage appears early, causing general cytolysis (evidenced by elevated transaminases), accompanied by a decrease in both serum ceruloplasmin and copper levels. Copper release from the liver may be moderate and/or sporadic in these initial stages, thus explaining normal cuprurias and the absence of extrahepatic deposits, hence the absence of neurological features. Later in life, the disease evolves to cirrhosis and neurological damage with variable penetrance.
The authors thank the patients and their families for their participation in the present study and the excellent service provided by Dr Javier García at Sistemas Genómicos SL.
1. Brewer GJ. Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis and Management
. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2001.
2. Pfeiffer RF. Wilson's disease. Semin Neurol
3. Bull PC, Thomas GR, Rommens JM, et al. The Wilson's disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature Genet
4. Petrukhin KE, Lutsenko S, Chernov I, et al. Characterization of Wilson's disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. Hum Molec Genet
5. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson's disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nature Genet
6. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun
7. Das SK, Ray K. Wilson's disease: an update. Nat Clin Pract Neurol
8. Kenney SM, Cox DW. Sequence variation database for the Wilson disease copper transporter, ATP7B. Hum Mutat
9. Buiakova OI, Xu J, Lutsenko S, et al. Null mutation of the murine ATP7B
(Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet
10. Huster D, Finegold MJ, Morgan CT, et al. Consequences of copper accumulation in the livers of the Atp7b−/− (Wilson disease gene) knockout mice. Am J Pathol
11. Ferenci P. Regional distribution of mutations of the ATP7B
gene in patients with Wilson disease: impact on genetic testing. Hum Genet
12. Zappu A, Magli O, Lepori M, et al. High incidence and allelic homogeneity of Wilson disease in 2 isolated populations: a prerequisite for efficient disease prevention programs. J Pediatr Gastroenterol Nutr
13. García-Villarreal L, Daniels S, Shaw SH, et al. High prevalence of the very rare Wilson disease gene mutation Leu708Pro in the island of Gran Canaria (Canary Islands, Spain): a genetic and clinical study. Hepatology
14. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int
15. Martins da Costa C, Baldwin D, Portmann B, et al. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology
16. Steindl P, Ferenci P, Dienes HP, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology
17. Sánchez-Albisua I, Garde T, Hierro L, et al. High index of suspicion: the key to an early diagnosis of Wilson's disease in childhood. J Pediatr Gastroenterol Nutr
18. Merle U, Schaefer M, Ferenci P, et al. Clinical presentation, diagnosis and long-term outcome of Wilson disease-a cohort study. Gut
19. Abdelghaffar TY, Elsayed SM, Elsobky E, et al. Mutational analysis of ATP7B
gene in Egyptian children with Wilson disease: 12 novel mutations. J Hum Genet
20. Manolaki N, Nikolopoulou G, Daikos GL, et al. Wilson disease in children: analysis of 57 cases. J Pediatr Gastroenterol Nutr
21. Nicastro E, Ranucci G, Vajro P, et al. Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. Hepatology
22. Thomas GR, Forbes JR, Roberts EA, et al. The Wilson's disease gene: spectrum of mutations and their consequences. Nat Genet
23. Shah AB, Chernov I, Zhang HT, et al. Identification and analysis of mutations in the Wilson's disease gene (ATP7B
): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet
24. Kalinsky H, Funes A, Zeldin A, et al. Novel ATP7B mutations causing Wilson's disease in several Israeli ethnic groups. Hum Mutat
25. Maier-Dobersberger T, Ferenci P, Polli C, et al. Detection of the His1069Gln mutation in Wilson's disease by rapid polymerase chain reaction. Ann Intern Med
26. Cox DW, Fraser FC, Sass-Kortsak A. A genetic study of Wilson's disease: evidence for heterogeneity. Am J Hum Genet
27. Senzolo M, Loreno M, Fagiuoli S, et al. Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins. Clin Neurol Neurosurg
28. Takeshita Y, Shimizu N, Yamaguchi Y, et al. Two families with Wilson disease in which siblings showed different phenotypes. J Hum Genet
29. Miller SA, Dykes DD, Olesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res
30. Curtis D, Durkie M, Balac P, et al. A study of Wilson disease mutations in Britain. Hum Mutat
31. Aravind L, Galperin MY, Koonin EV. The catalytic domain of the P-type ATPase has the haloacid dehalogenase fold. Trends Biochem Sci
32. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol
33. Scheuer PJ, Lefkowich JH. Liver Biopsy Interpretation
. 6th ed. Philadelphia: WB Saunders; 2000.
34. Deguti MM, Genschel J, Cancado EL, et al. Wilson disease: novel mutations in the ATP7B
gene and clinical correlation in Brazilian patients. Hum Mutat
35. Margarit E, Bach V, Gómez D, et al. Mutation analysis of Wilson disease in the Spanish population—identification of a prevalent substitution and eight novel mutations in the ATP7B gene. Clin Genet
36. Brage A, Tomé S, García A, et al. Clinical and molecular characterization of Wilson disease in Spanish patients. Hepatol Res
37. Jara Vega P, Hierro Llanillo L. Wilson's disease: forms of presentation in childhood. Gastroenterol Hepatol
38. Cheah DM, Deal YJ, Wright PF, et al. Heterozygous tx mice have an increased sensitivity to copper loading: implications for Wilson's disease carriers. Biometals
39. de Bie P, Muller P, Wijmenga C, et al. Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. J Med Genet
40. Sechi G, Antonio Cocco G, Errigo A, et al. Three sisters with very-late-onset major depression and parkinsonism. Parkinsonism Relat Disord
41. Iorio R, Sepe A, Giannattasio A, et al. Hypertransaminasemia in childhood as a marker of genetic liver disorders. J Gastroenterol
42. Sokol RJ, Narkewicz MR. Suchy FJ, Sokol RJ, Balistreri WF. Copper and iron storage disorders. Liver Disease in Children
. Philadelphia:Lippincott Williams & Wilkins; 2001. 595–647.
43. Dhawan A, Taylor RM, Cheeseman P, et al. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl
44. Milkiewicz P, Saksena S, Hubscher SG, et al. Wilson's disease with superimposed autoimmune features: report of two cases and review. J Gastroenterol Hepatol
45. Iorio R, D’Ambrosi M, Marcellini M, et al. Serum transaminases in children with Wilson's disease. J Pediatr Gastroenterol Nutr
46. Marcellini M, Di Ciommo V, Callea F, et al. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J Lab Clin Med
47. Arnon R, Calderon JF, Schilsky M, et al. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. J Pediatr Gastroenterol Nutr
48. Masełbas W, Chabik G, Członkowska A. Persistence with treatment in patients with Wilson disease. Neurol Neurochir Pol
49. Wiggelinkhuizen M, Tilanus ME, Bollen CW, et al. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther
50. Schiefermeier M, Kollegger H, Madl C, et al. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease. Brain
Keywords:Copyright 2012 by ESPGHAN and NASPGHAN
genetics; liver pathology; pediatric; rare mutation; Wilson disease